×

Tag: Matthew O'Connor

Matthew O'Connor
Recently, Cyclarity Therapeutics announced the launch of a Phase 1 human clinical trial for a drug that aims to remove the arterial plaques that lead to heart attacks and strokes. Tackling the leading cause of death worldwide Cyclarity Therapeutics is working on a cost-effective small molecule drug aimed at eliminating arterial plaque, thus potentially addressing...
Matthew O'Connor Interview
Cyclarity Therapeutics is striving to make powerful treatments for cardiovascular disease and, most importantly, make them accessible and affordable. Their cutting-edge cyclodextrin technology targets atherosclerosis, aiming to eliminate the buildup of non-degradable oxidized cholesterol that gets stuck inside cells in the arterial walls. The company has made great progress towards launching its cyclodextrin drug for...
Last Wednesday, I landed in Berlin, Germany at around 12:30. About an hour later, I was briefly in Cafè Alex, right next to the tapering TV Tower, where I met some of my colleagues from LEAF—some of whom I had never seen in person before—as well as other volunteers and members of HEALES, our friend...